Noscapine

Drug Profile

Noscapine

Alternative Names: CB 3304; Narcotine; NSC 5366

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emory University
  • Developer Cougar Biotechnology; University of Southern California
  • Class Alkaloids; Antineoplastics; Antitussives; Isoquinolines; Opiate alkaloids; Small molecules
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 10 Jul 2009 Cougar Biotechnology has been acquired by Johnson and Johnson
  • 22 Dec 2007 Phase-I/II clinical trials in Multiple myeloma in USA (PO)
  • 23 Jul 2007 Cougar receives allowance of IND for noscapine for the treatment of multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top